Sutro Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	65.93	190.3	69.27	47.25	30.41	206.15
Short-Term Investments	101.67	126.59	306.35	287.11	167.52	161.99
Cash & Short-Term Investments	167.59	316.9	375.62	334.36	197.94	368.14
Cash Growth	-56.83%	-15.63%	12.34%	68.92%	-46.23%	212.34%
Receivables	3.92	8.62	36.08	7.12	12.45	5.56
Prepaid Expenses	10.6	17.8	9.85	11.67	8.12	4.49
Total Current Assets	182.11	343.31	421.54	353.15	218.52	378.18
Property, Plant & Equipment	26.69	35.87	44.76	51.06	51.59	12.94
Long-Term Investments	-	-	-	-	68.78	-
Other Long-Term Assets	0.86	8.03	4.44	2.73	2.53	2.99
Total Assets	209.66	387.21	470.74	406.94	341.41	394.11
Accounts Payable	7.03	10.48	9.44	4.8	6.01	5.54
Accrued Expenses	32.14	40.13	34.1	24.83	17.07	8.82
Current Portion of Long-Term Debt	-	-	4.06	12.5	9.38	-
Current Portion of Leases	7.96	7.48	6.42	4.59	1.04	-
Current Income Taxes Payable	-	0.02	15.17	-	-	-
Current Unearned Revenue	8.98	69.78	20.67	16.76	5.5	14.6
Other Current Liabilities	15.79	4.01	3.9	3.08	2.75	0.63
Total Current Liabilities	71.9	131.89	93.75	66.55	41.74	29.6
Long-Term Debt	-	-	-	3.77	15.74	24.55
Long-Term Leases	9.7	15.67	23.15	29.57	31.22	-
Long-Term Unearned Revenue	213.64	193.35	202.49	89.89	-	6.1
Other Long-Term Liabilities	1.69	1.69	1.69	0.12	0.15	1.82
Total Liabilities	296.93	342.61	321.09	189.9	88.84	62.06
Common Stock	0.09	0.08	0.06	0.06	0.05	0.05
Additional Paid-In Capital	843.81	831.35	708.98	670.22	586.24	559.75
Retained Earnings	-931.19	-786.87	-559.41	-452.62	-333.41	-227.87
Comprehensive Income & Other	0.03	0.04	0.02	-0.62	-0.31	0.13
Total Common Equity	-87.27	44.6	149.65	217.05	252.56	332.05
Shareholders' Equity	-87.27	44.6	149.65	217.05	252.56	332.05
Total Liabilities & Equity	209.66	387.21	470.74	406.94	341.41	394.11
Total Debt	17.66	23.15	33.64	50.43	57.37	24.55
Net Cash (Debt)	149.93	293.74	341.98	283.93	209.34	343.59
Net Cash Growth	-58.74%	-14.11%	20.45%	35.63%	-39.07%	177.99%
Net Cash Per Share	17.90	38.23	56.84	55.96	45.39	105.48
Filing Date Shares Outstanding	8.51	8.38	6.24	6.02	4.64	4.59
Total Common Shares Outstanding	8.51	8.25	6.1	5.75	4.63	4.58
Working Capital	110.22	211.42	327.8	286.61	176.78	348.59
Book Value Per Share	-10.25	5.40	24.53	37.75	54.52	72.58
Tangible Book Value	-87.27	44.6	149.65	217.05	252.56	332.05
Tangible Book Value Per Share	-10.25	5.40	24.53	37.75	54.52	72.58
Machinery	-	42.12	40	37.63	31.82	32.79
Construction In Progress	-	0.5	0.5	1.69	0.51	1.08
Leasehold Improvements	-	24.21	23.61	23.22	23.65	15.9

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q